Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.[1]
It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses.[2]
- Market Cap ₹ 52,117 Cr.
- Current Price ₹ 1,540
- High / Low ₹ 1,750 / 1,242
- Stock P/E 42.2
- Book Value ₹ 180
- Dividend Yield 0.91 %
- ROCE 18.9 %
- ROE 18.3 %
- Face Value ₹ 5.00
Pros
- Company has been maintaining a healthy dividend payout of 68.2%
Cons
- Stock is trading at 8.55 times its book value
- The company has delivered a poor sales growth of 7.91% over past five years.
- Company might be capitalizing the interest cost
- Working capital days have increased from 56.2 days to 88.9 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2,195 | 2,691 | 3,203 | 4,172 | 4,636 | 6,687 | 5,816 | 5,950 | 7,673 | 7,939 | 8,005 | 8,508 | 9,260 | |
1,807 | 2,189 | 2,506 | 3,216 | 3,616 | 3,954 | 4,438 | 4,601 | 5,690 | 5,769 | 5,524 | 6,077 | 6,584 | |
Operating Profit | 389 | 502 | 697 | 955 | 1,020 | 2,733 | 1,377 | 1,349 | 1,983 | 2,170 | 2,480 | 2,431 | 2,676 |
OPM % | 18% | 19% | 22% | 23% | 22% | 41% | 24% | 23% | 26% | 27% | 31% | 29% | 29% |
55 | -22 | 1 | 34 | 286 | 32 | 223 | 299 | -300 | 121 | 57 | -288 | -393 | |
Interest | 39 | 39 | 34 | 59 | 175 | 184 | 206 | 308 | 504 | 451 | 353 | 255 | 283 |
Depreciation | 63 | 82 | 83 | 87 | 191 | 238 | 307 | 409 | 618 | 654 | 658 | 662 | 673 |
Profit before tax | 342 | 359 | 582 | 844 | 940 | 2,343 | 1,088 | 931 | 562 | 1,187 | 1,526 | 1,226 | 1,327 |
Tax % | 21% | 20% | 25% | 21% | 20% | 26% | 14% | 27% | 22% | 14% | 18% | 37% | |
Net Profit | 270 | 286 | 435 | 664 | 751 | 1,733 | 934 | 678 | 436 | 1,025 | 1,252 | 777 | 831 |
EPS in Rs | 7.98 | 8.39 | 12.79 | 19.62 | 22.19 | 51.22 | 27.59 | 20.04 | 12.89 | 30.28 | 36.99 | 22.97 | 24.55 |
Dividend Payout % | 25% | 25% | 45% | 25% | 25% | 34% | 25% | 35% | 66% | 53% | 47% | 105% |
Compounded Sales Growth | |
---|---|
10 Years: | 12% |
5 Years: | 8% |
3 Years: | 4% |
TTM: | 11% |
Compounded Profit Growth | |
---|---|
10 Years: | 13% |
5 Years: | 4% |
3 Years: | 22% |
TTM: | 1% |
Stock Price CAGR | |
---|---|
10 Years: | 24% |
5 Years: | 20% |
3 Years: | 18% |
1 Year: | 10% |
Return on Equity | |
---|---|
10 Years: | 24% |
5 Years: | 18% |
3 Years: | 21% |
Last Year: | 18% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
42 | 42 | 42 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 169 | |
Reserves | 980 | 1,152 | 1,380 | 1,818 | 2,406 | 3,409 | 4,266 | 4,538 | 4,640 | 4,739 | 5,753 | 5,868 | 5,922 |
572 | 579 | 693 | 1,132 | 2,740 | 2,352 | 2,510 | 6,462 | 6,038 | 5,784 | 4,874 | 4,070 | 4,083 | |
941 | 1,275 | 1,638 | 1,988 | 2,589 | 3,040 | 2,740 | 3,159 | 3,351 | 3,402 | 3,363 | 2,884 | 3,045 | |
Total Liabilities | 2,536 | 3,048 | 3,753 | 5,022 | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 13,219 |
636 | 797 | 820 | 875 | 2,833 | 2,859 | 3,688 | 7,855 | 7,748 | 7,533 | 7,065 | 6,423 | 6,499 | |
CWIP | 180 | 119 | 285 | 534 | 678 | 1,042 | 519 | 647 | 617 | 712 | 889 | 630 | 609 |
Investments | 146 | 124 | 60 | 186 | 298 | 780 | 804 | 492 | 353 | 2 | 181 | 226 | 505 |
1,574 | 2,008 | 2,587 | 3,427 | 4,011 | 4,206 | 4,589 | 5,249 | 5,395 | 5,763 | 5,940 | 5,628 | 5,606 | |
Total Assets | 2,536 | 3,048 | 3,753 | 5,022 | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 13,219 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
395 | 486 | 153 | 599 | 810 | 2,742 | 1,009 | 894 | 1,798 | 1,393 | 2,005 | 1,803 | |
-233 | -137 | -247 | -418 | -2,113 | -869 | -798 | -4,677 | -246 | 229 | -444 | -196 | |
-68 | -193 | 20 | 86 | 1,212 | -1,435 | -193 | 3,417 | -1,314 | -1,549 | -1,651 | -1,781 | |
Net Cash Flow | 94 | 156 | -73 | 268 | -90 | 437 | 18 | -366 | 238 | 73 | -89 | -174 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 57 | 71 | 78 | 96 | 125 | 79 | 60 | 77 | 68 | 76 | 69 | 70 |
Inventory Days | 265 | 225 | 364 | 297 | 275 | 314 | 318 | 429 | 318 | 362 | 456 | 368 |
Days Payable | 322 | 365 | 421 | 421 | 472 | 523 | 356 | 447 | 345 | 345 | 351 | 250 |
Cash Conversion Cycle | -1 | -69 | 22 | -28 | -71 | -130 | 21 | 59 | 42 | 93 | 174 | 188 |
Working Capital Days | -4 | 0 | 33 | 42 | 54 | -1 | 28 | 20 | -17 | -2 | 82 | 89 |
ROCE % | 25% | 27% | 33% | 35% | 27% | 48% | 19% | 13% | 13% | 15% | 17% | 19% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 2d
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 17 Mar
-
USFDA Pre-Approval Inspection Of Oral Oncology Manufacturing Facility, Gujarat
17 Mar - USFDA conducted Pre-Approval Inspection [PAI] of our Oral-Oncology manufacturing facility at Bileshwarpura, Gujarat from 13-Mar-23 to 17-Mar-23. At the end of the inspection, we have …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Mar - Newspaper advertisement in respect of Notice of Hearing of Petition Ref : Scheme of Arrangement in the nature of Amalgamation of Curatio Health Care (I) …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
18 Feb - Of Schedule of Investors Meet under Regulation 30 of SEBI (LODR) Regulations, 2015
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
Sep 2022TranscriptNotesPPT
-
May 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Jul 2020TranscriptPPT
-
May 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Oct 2018TranscriptPPT
-
Jul 2018Transcript PPT
-
May 2018Transcript PPT
-
Feb 2018Transcript PPT
-
Feb 2018TranscriptNotesPPT
-
Oct 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Jan 2017TranscriptPPT
-
Oct 2016TranscriptPPT
-
May 2016TranscriptPPT
Product Offerings
The company manufactures pharmaceutical products under various dosage forms such as oral solids, oral liquids, topicals, suppositories, Human insulin and synthetic APIs. API manufacturing is predominantly aimed at captive consumption.[1]